Johnson & Johnson News, Research and Articles --GuruFocus.com

JNJ- NYSE (USA) Also traded in: Argentina, Austria, Brazil, Chile, Germany, Mexico, Switzerland, UK
Johnson & Johnson

Currently 2.5/5

Business Predictability Rank: 2.5-Star
Back Testing Results:
Average gain of all 2.5-Star stocks: 7.3% per year.
% of Stocks that are in still loss if held for 10yrs: 18%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies

$130.83

0.12(0.09%) Volume: 5,811,784 4:01PM EDT

Avg Vol (1m): 6,187,610

6 Medium Warning Signs 2 Good Signs

Market Cap : 352.43 B	Enterprise Value : 345.46 B	P/E(TTM) : 22.11	P/B : 5.04

RSS

Manual of Stocks™ Web APP

Manual of Stocks™

Sorry. Only PremiumPlus Member can access this feature.

Free Trial

More From Other Websites

[$$] United Therapeutics in Settlement Talks With Justice Department Jul 27 2017

Johnson & Johnson breached its 50 day moving average in a Bearish Manner : JNJ-US : July 27, 2017 Jul 27 2017

What Led the Rise in GE’s Healthcare Revenue in 2Q17? Jul 27 2017

Ignore the Obamacare fight in Congress and buy these 5 health-care stocks Jul 27 2017

Bavarian expands J&J deal to HIV and hepatitis B vaccines, shares jump Jul 27 2017

GlaxoSmithKline's new boss streamlines R&D, axes slew of drugs Jul 26 2017

Here's Why Integra LifeSciences Holdings Corp. Is Sinking Today Jul 26 2017

Turn Pocket Change Into Millions With Seven Dividend-Paying Stocks Jul 26 2017

Eli Lilly: The Competition is Just Too Darn Intense! Jul 26 2017

Earnings Preview: What To Expect From Starbucks On Thursday Jul 26 2017

3 Charts Suggesting Traders Are Bullish on Healthcare Jul 26 2017

The Supreme Court Delivers a Blow to Plaintiff Paradise Jul 26 2017

Senate Votes to Approve Motion to Proceed on Health Care Jul 25 2017

3 Dividend Stocks That Are Perfect for Retirement Jul 25 2017

Report: More than 15,000 Adverse Events Linked to Xarelto in 2016 Jul 25 2017

4 Benefits ETF Investing May Add To Your Portfolio Jul 25 2017

Drug Stocks Q2 Earnings Releases on Jul 26: GILD, VRTX, GSK Jul 25 2017

What's in the Cards for Geron (GERN) this Earnings Season? Jul 25 2017

Stock Market News for July 25, 2017 Jul 25 2017

Are Brands Back on YouTube? Jul 25 2017

Total Records: 940 Page:

1 2 3 4 5 6 7 8 9 10

LAST (24)

40 per page ▾

10 20 25 30 50 100

- Currently 0.00/5
Rating: 0.0/5 (0 votes)
Health Care Companies Showing Good Defensive Potential - Dec. 22, 2016
- Currently 0.00/5
Rating: 0.0/5 (0 votes)
Donald Yacktman Reduces Multiple Positions in 3rd Quarter - Dec. 21, 2016
- Currently 0.00/5
Rating: 0.0/5 (0 votes)
US Market Indexes Mixed on Monday - Dec. 12, 2016
- Currently 5.00/5
Rating: 5.0/5 (1 vote)
Tweedy Browne Fund Investment Adviser's Semi-Annual Letter to Shareholders - Nov. 28, 2016
- Currently 0.00/5
Rating: 0.0/5 (0 votes)
Johnson & Johnson's Janssen Pharmaceutical Starts Study on Hepatitis C Therapy - Nov. 28, 2016
- Currently 5.00/5
Rating: 5.0/5 (1 vote)
US Market Indexes Lower to Start the Week - Nov. 28, 2016
- Currently 0.00/5
Rating: 0.0/5 (0 votes)
Small-Cap Biotech Is on Front Lines of Fight Against Depression - Nov. 22, 2016
- Currently 0.00/5
Rating: 0.0/5 (0 votes)
Richard Perry Exits AIG, Time Warner - Nov. 14, 2016
- Currently 0.00/5
Rating: 0.0/5 (0 votes)
RA Drug Comparison Yields Mixed Results - Nov. 14, 2016
- Currently 5.00/5
Rating: 5.0/5 (1 vote)
Johnson & Johnson Expect it to Deliver Consistent Results - Nov. 08, 2016
- Currently 5.00/5
Rating: 5.0/5 (1 vote)
Samuel Isaly Makes 9 New Buys in 3rd Quarter - Nov. 04, 2016
- Currently 0.00/5
Rating: 0.0/5 (0 votes)
Dividend Aristocrats in Focus Part 24: Johnson & Johnson - Nov. 01, 2016
- Currently 0.00/5
Rating: 0.0/5 (0 votes)
AbbVie Reports 3rd Quarter Results - Nov. 01, 2016
- Currently 4.00/5
Rating: 4.0/5 (1 vote)
The Pharmaceutical Sector Looks Attractive - Oct. 12, 2016
- Currently 0.00/5
Rating: 0.0/5 (0 votes)
US Market Indexes Lower on Tuesday - Oct. 11, 2016
- Currently 0.00/5
Rating: 0.0/5 (0 votes)
Dividend Aristocrats in Focus, Part 1: Consolidated Edison - Oct. 11, 2016
- Currently 0.00/5
Rating: 0.0/5 (0 votes)
BeiGene Presents First Clinical Data for New Cancer Treatment - Oct. 07, 2016
- Currently 4.13/5
Rating: 4.1/5 (8 votes)
What Rate of Return Will an Investment in Johnson & Johnson Deliver? Part 2 - Oct. 05, 2016
- Currently 0.00/5
Rating: 0.0/5 (0 votes)
Immune Design Insider Buys Shares - Oct. 03, 2016
- Currently 0.00/5
Rating: 0.0/5 (0 votes)
Johnson & Johnson: Bull Rally to Continue? - Oct. 01, 2016
- Currently 4.33/5
Rating: 4.3/5 (6 votes)
Valuation Is a Measurement of Soundness and Not the Primary Total Return Producer: Part 1 - Sep. 29, 2016
- Currently 4.00/5
Rating: 4.0/5 (1 vote)
Ratings on the Largest Stocks – Buy, Neutral or Avoid - Sep. 28, 2016
- Currently 5.00/5
Rating: 5.0/5 (1 vote)
Ariel Funds Comments on Johnson & Johnson - Sep. 28, 2016
- Currently 5.00/5
Rating: 5.0/5 (1 vote)
John Rogers' Ariel Global Fund 2nd Quarter Commentary - Sep. 28, 2016
- Currently 3.00/5
Rating: 3.0/5 (1 vote)
J&J Finally Returning to Its Roots in Diversity? - Sep. 26, 2016
- Currently 5.00/5
Rating: 5.0/5 (3 votes)
The 5 Most-Sold Stocks of All US Investment Funds - Sep. 23, 2016
- Currently 0.00/5
Rating: 0.0/5 (0 votes)
John Paulson Trims Synergy - Sep. 23, 2016
- Currently 0.00/5
Rating: 0.0/5 (0 votes)
Sanofi in a State of Suspended Animation Until Boehringer Ingelheim Swap - Sep. 19, 2016
- Currently 1.00/5
Rating: 1.0/5 (3 votes)
Did Warren Buffet Just Call a 2016 Stock Market Crash? - Sep. 19, 2016
- Currently 0.00/5
Rating: 0.0/5 (0 votes)
Is Johnson & Johnson Backing Away From a Growing Medical Devices Market? - Sep. 15, 2016
- Currently 0.00/5
Rating: 0.0/5 (0 votes)
The Smallest Dividend King: Growth & Acquisitions - Sep. 15, 2016
- Currently 2.33/5
Rating: 2.3/5 (3 votes)
Interview With George Athanassakos - Sep. 15, 2016
- Currently 5.00/5
Rating: 5.0/5 (4 votes)
Mark Twain Says Pile Out - Sep. 07, 2016
- Currently 5.00/5
Rating: 5.0/5 (1 vote)
Royal Bank of Canada: Minor Risks, Major Returns and Mean Reversion - Sep. 06, 2016
- Currently 0.00/5
Rating: 0.0/5 (0 votes)
Tobacco Producer Has More Than 50% Upside Potential - Sep. 01, 2016
- Currently 0.00/5
Rating: 0.0/5 (0 votes)
Eli Lilly's Future Is Changing - Aug. 30, 2016
- Currently 4.00/5
Rating: 4.0/5 (2 votes)
Can Novartis Tide Over the Alcon Crisis? - Aug. 26, 2016
- Currently 0.00/5
Rating: 0.0/5 (0 votes)
Tight Trading on Thursday with Stocks Ending Lower - Aug. 25, 2016
- Currently 0.00/5
Rating: 0.0/5 (0 votes)
Healthcare Drug Pricing a Factor for the Market on Wednesday - Aug. 24, 2016
- Currently 0.00/5
Rating: 0.0/5 (0 votes)
Merck Offers Value and Steady Dividend Growth - Aug. 24, 2016

Total Records: 940 Page:

1 2 3 4 5 6 7 8 9 10

LAST (24)

40 per page ▾

10 20 25 30 50 100

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

Home About Jobs Advertise Site Map Term of Use Privacy Policy RSS Mobile App Email Alerts Referral Program Affiliate Program FAQ Contact Us
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.

GF Chat

Value Screens

Downloads | Tools

Strategies

Market Valuation

By Country

Articles

Submit Articles

Add Notes, Comments